-
March 2010: Bayer Says It Will Update Yasmin Label In Europe To Add Results From Four Medical Studies
Two Newer Studies Found An Increased Venous Thromboembolism (VTE) Risk in Yasmin Users Compared To Levonorgestrel-Containing Birth Control Pills (Posted by Tom Lamb at DrugInjuryWatch.com) ________________________________________________________________________________________ UPDATE: New research suggests that women who use oral…
-
New Extensively Documented Case Report About Patient With Probable Byetta-Induced Pancreatitis
Numerous Factors, Including Temporal Relation Of Symptoms To Drug Use Dates And A Naranjo Scale Score Of 7/9, Strongly Suggest Byetta Caused This Case Of Acute Pancreatitis (Posted by Tom Lamb at DrugInjuryWatch.com) On March 25,…
-
Antibiotic Avelox Linked To Severe Liver Injury Side Effects, Again
Will The FDA Be The Last To Insist On Increased Warning; In Fall 2007 Bayer Updated Its Avalox Label In Europe (Posted by Tom Lamb at DrugInjuryWatch.com) On March 22, 2010 Health Canada issued a press…
-
March 2010: FDA Warns About Highest Dose Of Zocor Causing Myopathy And Rhabdomyolysis
Active Ingredient Simvastatin Is Found In Vytorin, With Zetia, And Simcor, With Niacin, Also (Posted by Tom Lamb at DrugInjuryWatch.com) _________________________________________________________________________________________ UPDATE: FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor…
-
FDA And Novartis Announce A Label Change For Iron Chelating Drug Exjade In Mid-February 2010
Includes A New "Black Box" Warning About Renal Impairment, Liver Failure, And Gastrointestinal Hemorrhage (Posted by Tom Lamb at DrugInjuryWatch.com) In mid-February 2010 the FDA and Novartis announced a change to the Prescribing Information…
-
Focus On Fosamax
________________________________________________________ Free Fosamax Case Evaluation The information you provide to us for this Free Case Evaluation will be treated as strictly confidential. You will get a reply from us no later than the next business…
